Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for Symptom Burden in ASCT for Multiple Myeloma and AL Amyloidosis
NCT03315026Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2017
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in multiple myeloma (MM), amyloid light chain amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2017; status: active, not recruiting.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03315026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315026.